Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star 1 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 1 again. I would not like to hand the conference over to your speaker today. David Connolly, Investor Relations at Rhythm. Thank you, Josh. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com. This morning, we issued our press release that provides our Q1 2025 financial results and a business update, and that press release is available on our website. Our agenda is listed on slide two. On the call today are David Meeker, our chairman and chief executive officer and president, Jennifer Lee, executive vice president, head of North America, Hunter Smith, chief financial officer, and Jan Mazzebro, executive vice president, head of international, is on the line and joining us from Europe. On slide three, I'll remind you that this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed on our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of today and sh...